Financial Services >> Analyst Interviews >> September 23, 2003

Later Stage Venture Transactions: Kee Colen – Oppenheimer & Co Inc

KEE COLEN, Senior Vice President, has been providing investment banking services to emerging growth and middle market companies for 15 years. His industry focus is health care, including the biotechnology, specialty pharmaceutical and medical technology sectors. He has completed over 75 transactions including initial and follow-on public offerings, PIPEs, other private placements of equity, mezzanine and debt capital, M&A advisory, valuations and fairness opinions. He joined Oppenheimer's predecessor, Fahnestock & Co. Inc., in 1994 through the acquisition of Reich & Co. Inc. Prior to Reich, he was an Investment Banking Associate at Rosenkrantz, Lyon & Ross and a Research Analyst in the municipal bond department at Van Kampen Merritt. He has a BS in Finance from Northern Illinois University where he graduated magna cum laude and an MBA from Indiana University. Profile
TWST: Would you give us a quick overview of Oppenheimer's involvement in

the private equity market?

Mr. Colen: Our position in the private equity market is working on later

stage venture